These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 33797740)

  • 1. Umbralisib: First Approval.
    Dhillon S; Keam SJ
    Drugs; 2021 May; 81(7):857-866. PubMed ID: 33797740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study.
    Burris HA; Flinn IW; Patel MR; Fenske TS; Deng C; Brander DM; Gutierrez M; Essell JH; Kuhn JG; Miskin HP; Sportelli P; Weiss MS; Vakkalanka S; Savona MR; O'Connor OA
    Lancet Oncol; 2018 Apr; 19(4):486-496. PubMed ID: 29475723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies.
    Davids MS; O'Connor OA; Jurczak W; Samaniego F; Fenske TS; Zinzani PL; Patel MR; Ghosh N; Cheson BD; Derenzini E; Brander DM; Reeves JA; Knopińska-Posłuszny W; Allan JN; Phillips T; Caimi PF; Lech-Maranda E; Burke JM; Agajanian R; Pettengell R; Leslie LA; Cheah CY; Fonseca G; Essell J; Chavez JC; Pagel JM; Sharman JP; Hsu Y; Miskin HP; Sportelli P; Weiss MS; Flinn IW
    Blood Adv; 2021 Dec; 5(23):5332-5343. PubMed ID: 34547767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma.
    Fowler NH; Samaniego F; Jurczak W; Ghosh N; Derenzini E; Reeves JA; Knopińska-Posłuszny W; Cheah CY; Phillips T; Lech-Maranda E; Cheson BD; Caimi PF; Grosicki S; Leslie LA; Chavez JC; Fonseca G; Babu S; Hodson DJ; Shao SH; Burke JM; Sharman JP; Law JY; Pagel JM; Miskin HP; Sportelli P; O'Connor OA; Weiss MS; Zinzani PL
    J Clin Oncol; 2021 May; 39(15):1609-1618. PubMed ID: 33683917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study.
    Davids MS; Kim HT; Nicotra A; Savell A; Francoeur K; Hellman JM; Bazemore J; Miskin HP; Sportelli P; Stampleman L; Maegawa R; Rueter J; Boruchov AM; Arnason JE; Jacobson CA; Jacobsen ED; Fisher DC; Brown JR;
    Lancet Haematol; 2019 Jan; 6(1):e38-e47. PubMed ID: 30558987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The evidence to date on umbralisib for the treatment of refractory marginal zone lymphoma and follicular lymphoma.
    Schweitzer J; Hoffman M; Graf SA
    Expert Opin Pharmacother; 2022 Apr; 23(5):535-541. PubMed ID: 35209784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Copanlisib: First Global Approval.
    Markham A
    Drugs; 2017 Dec; 77(18):2057-2062. PubMed ID: 29127587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Duvelisib: First Global Approval.
    Blair HA
    Drugs; 2018 Nov; 78(17):1847-1853. PubMed ID: 30430368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDA Evaluating Possible Serious Risks From Umbralisib.
    Aschenbrenner DS
    Am J Nurs; 2022 Jun; 122(6):23. PubMed ID: 35617560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy.
    Mato AR; Ghosh N; Schuster SJ; Lamanna N; Pagel JM; Flinn IW; Barrientos JC; Rai KR; Reeves JA; Cheson BD; Barr PM; Kambhampati S; Lansigan F; Pu JJ; Skarbnik AP; Roeker L; Fonseca GA; Sitlinger A; Hamadeh IS; Dorsey C; LaRatta N; Weissbrot H; Luning Prak ET; Tsao P; Paskalis D; Sportelli P; Miskin HP; Weiss MS; Svoboda J; Brander DM
    Blood; 2021 May; 137(20):2817-2826. PubMed ID: 33259589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.
    Lunning M; Vose J; Nastoupil L; Fowler N; Burger JA; Wierda WG; Schreeder MT; Siddiqi T; Flowers CR; Cohen JB; Sportelli P; Miskin HP; Weiss MS; O'Brien S
    Blood; 2019 Nov; 134(21):1811-1820. PubMed ID: 31558467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The dual PI3Kδ/CK1ε inhibitor umbralisib exhibits unique immunomodulatory effects on CLL T cells.
    Maharaj K; Powers JJ; Achille A; Mediavilla-Varela M; Gamal W; Burger KL; Fonseca R; Jiang K; Miskin HP; Maryanski D; Monastyrskyi A; Duckett DR; Roush WR; Cleveland JL; Sahakian E; Pinilla-Ibarz J
    Blood Adv; 2020 Jul; 4(13):3072-3084. PubMed ID: 32634240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design of Novel Phosphatidylinositol 3-Kinase Inhibitors for Non-Hodgkin's Lymphoma: Molecular Docking, Molecular Dynamics, and Density Functional Theory Studies on Gold Nanoparticles.
    Ali AM; Makki AA; Ibraheem W; Abdelrahman M; Osman W; Sherif AE; Ashour A; Ibrahim SRM; Ghazawi KF; Samman WA; Alzain AA
    Molecules; 2023 Mar; 28(5):. PubMed ID: 36903539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Idelalisib: first global approval.
    Markham A
    Drugs; 2014 Sep; 74(14):1701-7. PubMed ID: 25187123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Matching-Adjusted Indirect Comparison of Single-Arm Trials in Patients with Relapsed or Refractory Follicular Lymphoma Who Received at Least Two Prior Systemic Treatments: Tazemetostat was Associated with a Lower Risk for Safety Outcomes Versus the PI3-Kinase Inhibitors Idelalisib, Duvelisib, Copanlisib, and Umbralisib.
    Proudman D; Nellesen D; Gupta D; Adib D; Yang J; Mamlouk K
    Adv Ther; 2022 Apr; 39(4):1678-1696. PubMed ID: 35157216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma.
    Keating GM
    Drugs; 2010 Jul; 70(11):1445-76. PubMed ID: 20614951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma.
    Falchi L; Ferrajoli A; Jacobs I; Nava-Parada P
    Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):508-518.e14. PubMed ID: 29934061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study of the PI3K inhibitor copanlisib in combination with the anti-CD20 monoclonal antibody rituximab for patients with marginal zone lymphoma: treatment rationale and protocol design of the COUP-1 trial.
    Grunenberg A; Kaiser LM; Woelfle S; Schmelzle B; Viardot A; Möller P; Barth TFE; Muche R; Dreyhaupt J; Raderer M; Kiesewetter B; Buske C
    BMC Cancer; 2021 Jun; 21(1):749. PubMed ID: 34187401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Hagemeister F
    Drugs; 2010 Feb; 70(3):261-72. PubMed ID: 20166765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma.
    Flinn IW; Miller CB; Ardeshna KM; Tetreault S; Assouline SE; Mayer J; Merli M; Lunin SD; Pettitt AR; Nagy Z; Tournilhac O; Abou-Nassar KE; Crump M; Jacobsen ED; de Vos S; Kelly VM; Shi W; Steelman L; Le N; Weaver DT; Lustgarten S; Wagner-Johnston ND; Zinzani PL
    J Clin Oncol; 2019 Apr; 37(11):912-922. PubMed ID: 30742566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.